Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis (UCanADA)

22 januari 2021 bijgewerkt door: AbbVie

A Study of the Impact of Adalimumab on Patient-reported Outcomes (PROs) in Canadian Patients Suffering From Moderate-to-severe Ulcerative Colitis (UCanADA)

To evaluate the real-life effect after 1 year of adalimumab treatment on psychological distress/depression symptoms in moderate-to-severe Ulcerative Colitis (UC) patients.

Studie Overzicht

Toestand

Voltooid

Conditie

Studietype

Observationeel

Inschrijving (Werkelijk)

100

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 4Z6
        • University of Calgary /ID# 144032
      • Edmonton, Alberta, Canada, T6G 2X8
        • Zeidler Ledcor Centre /ID# 145973
    • British Columbia
      • New Westminster, British Columbia, Canada, V3L 3W5
        • Columbia Gastro Mgmnt Ltd /ID# 136820
      • Vancouver, British Columbia, Canada, V6Z 2K5
        • GIRI Gastrointestinal Research Institute /ID# 141107
      • Victoria, British Columbia, Canada, V8T 5G4
        • Discovery Clinical Services /ID# 144102
      • Victoria, British Columbia, Canada, V8V 3M9
        • Percuro Clinical Research, Ltd /ID# 136533
    • New Brunswick
      • Fredericton, New Brunswick, Canada, E3B 5N5
        • Dr. Everett Chalmers Reg Hosp. /ID# 136534
      • St. John, New Brunswick, Canada, E2K 1J5
        • Dr Chadwick Ian Williams Professional Corporation /ID# 144802
    • Ontario
      • Brampton, Ontario, Canada, L6S 0C1
        • Bellini Medicine Professional /ID# 144241
      • Oshawa, Ontario, Canada, L1H 1B9
        • Oshawa Clinic /ID# 144364
      • Ottawa, Ontario, Canada, K1H 8L6
        • The Ottawa Hospital /ID# 139392
      • Toronto, Ontario, Canada, M53 TA9
        • Kensington Screening Clinic /ID# 141106
      • Toronto, Ontario, Canada, M5G 1X5
        • Mount Sinai Hosp.-Toronto /ID# 141108
      • Windsor, Ontario, Canada, N8W 1E6
        • Dr O Tarabain Medicine Prof Corp /ID# 144034
      • Windsor, Ontario, Canada, N8Y 4C9
        • Dr. Rahman Bacchus Med. Corp. /ID# 141780
    • Quebec
      • Levis, Quebec, Canada, G6V 3Z1
        • Hopital Hotel-Dieu de Levis /ID# 137099
      • Montreal, Quebec, Canada, H1T 2M4
        • Hospital Maisonneuve-Rosemont /ID# 137336
      • Montreal, Quebec, Canada, H2X 3J4
        • CHUM - Hopital Saint-Luc /ID# 139393
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill Univ HC /ID# 136821
      • Montreal, Quebec, Canada, H3P 3E5
        • Clinique MEDI-CLE /ID# 153690
      • Quebec City, Quebec, Canada, G1R 2J6
        • CHU de Quebec-Universite Laval /ID# 147557
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • CHUS - Hopital Fleurimont /ID# 137840
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada, S7N 0W8
        • Royal Univ. Hosp, Saskatoon,CA /ID# 137838

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Adult males and females with moderate to severe UC patients from Canada who meet the inclusion criteria and who do not meet any of the exclusion criteria will be eligible for enrollment into the study.

Beschrijving

Inclusion Criteria:

  • Patient must voluntarily sign and date a patient authorization.
  • Patient must be ≥ 18 years of age.
  • Patient must have confirmed diagnosis of UC.

  • Patient must have:

    1. a Mayo endoscopic sub score of 2 or 3 from endoscopic investigation in the previous 3-months that is closest to the baseline visit or
    2. a Mayo rectal bleeding subscore ≥ 2 and a calprotectin value greater than 250 µg/gr.
  • Patient must have been prescribed adalimumab as part of his treatment by his treating physician.
  • If the patient was previously treated with vedolizumab or any anti-TNF agent (except adalimumab), an appropriate washout has taken place as per routine practice.

Exclusion Criteria:

  • Patient has previously received adalimumab.
  • Patient has previously used infliximab or any anti-TNF agent and have not clinically responded at any time ("primary non-responder") unless they experienced a treatment limiting reaction.
  • Patient with a history of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for UC or planned bowel surgery.
  • Patient with a current diagnosis of indeterminate colitis, ulcerative proctitis only, or with a current diagnosis and/or have a history of Crohn's disease.
  • Patient with other tumor necrosis factor (TNF) immune-modulated disease.
  • Patient has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the investigator would adversely affect his/her participating in this study.
  • A female patient is pregnant or breast-feeding.
  • Patient is currently participating in another prospective study including controlled clinical trials and observational studies

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: Cohort
  • Tijdsperspectieven: Prospectief

Cohorten en interventies

Groep / Cohort
Open-label cohort
Patients will be followed for 52 weeks post initiation of adalimumab (Week 0).

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from baseline in depressive symptoms at Week 52
Tijdsspanne: From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
It is measured by the Patient Health Questionnaire - 9 Items (PHQ-9).
From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from baseline in depressive symptoms at Week 8
Tijdsspanne: From Week 0 to Week 8, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
It is measured by the Patient Health Questionnaire - 9 Items (PHQ-9).
From Week 0 to Week 8, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
Change from baseline in the proportion of patients with PHQ-9 >= 10
Tijdsspanne: From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
The change from baseline in the proportion of patients with PHQ-9 >= 10 is assessed at week 8 and 52.
From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
Change from baseline in Disability
Tijdsspanne: From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
It is measured by the Inflammatory Bowel Disease (IBD) Disability Index at weeks 8 and 52.
From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
Change from baseline in Overall quality of life
Tijdsspanne: From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
It is measured by the EuroQol 5-Dimensions, 5 Levels (EQ-5D-5L) and EQ5D VAS at weeks 8 and 52.
From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
Change from baseline in Ulcerative Colitis (UC)-specific quality of life
Tijdsspanne: From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
It is measured by the Short Quality of Life in Inflammatory Bowel Disease Questionnaire (SIBDQ) at weeks 8 and 52.
From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
Change from baseline in Fatigue
Tijdsspanne: From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
It is measured by the Functional Assessment Chronic Illness Therapy-Fatigue (FACIT-F) at weeks 8 and 52.
From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
Change from baseline in Sleep impairment,
Tijdsspanne: From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
It is measured by the Medical Outcomes Study Sleep scale (MOS Sleep) at weeks 8 and 52.
From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
Change from baseline in Work productivity
Tijdsspanne: From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
The change from baseline in work productivity is assessed at week 8 and 52.
From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
Assessing Simple Clinical Colitis Activity Index (SCCAI)
Tijdsspanne: Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
SCCAI is used to access response and remission rates.
Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
Change from baseline in Fecal Calprotectin levels
Tijdsspanne: From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
The change from baseline in Fecal Calprotectin levels will be assessed.
From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
Mayo endoscopic sub-score
Tijdsspanne: Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
Mayo endoscopic sub-score will be assessed.
Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
Proportion of patients with Complications including hospitalization and surgery
Tijdsspanne: At Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
The proportion of patients with complications including hospitalization and surgery will be assessed.
At Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
Proportion of patients on steroids
Tijdsspanne: At Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
The proportion of patients on steroids will be assessed.
At Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
Change from baseline in Physician's Global Assessment (PGA)
Tijdsspanne: From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
The change from baseline in Physician's Global Assessment (PGA) will be assessed.
From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

AbbVie

Medewerkers

Cato Research

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Nuttige links

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

18 augustus 2015

Primaire voltooiing (Werkelijk)

10 februari 2020

Studie voltooiing (Werkelijk)

10 februari 2020

Studieregistratiedata

Eerst ingediend

26 juni 2015

Eerst ingediend dat voldeed aan de QC-criteria

21 juli 2015

Eerst geplaatst (Schatting)

23 juli 2015

Updates van studierecords

Laatste update geplaatst (Werkelijk)

25 januari 2021

Laatste update ingediend die voldeed aan QC-criteria

22 januari 2021

Laatst geverifieerd

1 januari 2021

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • P15-325

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

Onbeslist

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren